Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
Open Access
- 29 December 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 39 (2), 147-157
- https://doi.org/10.1007/s40264-015-0374-9
Abstract
Introduction Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for daily dosing. Objective The objective of these analyses was to compare the adverse event profile of dalbavancin with that of the comparator agents in the treatment of skin and skin structure infections. Methods Data on adverse events and laboratory assessments collected from 3002 patients enrolled in seven late-stage, randomized clinical trials were analyzed for patients receiving dalbavancin or a comparator antibiotic. Results Overall adverse event rates were similar or lower for patients receiving dalbavancin (799/1778; 44.9 %) compared with those receiving comparator agents (573/1224; 46.8 %, p = 0.012). The most common treatment-emergent adverse events were nausea, headache, diarrhea, constipation, vomiting, rash, urinary tract infection, pruritus, and insomnia. The duration and timing of the onset of adverse events were similar for patients receiving dalbavancin relative to the comparators. Conclusion Dalbavancin exhibits a favorable overall safety profile for treatment of acute bacterial skin and skin structure infections due to Gram-positive bacteria.Keywords
Funding Information
- Durata Therapeutics, Inc
This publication has 12 references indexed in Scilit:
- A thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infectionsInternational Journal of Antimicrobial Agents, 2015
- Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular TissueAntimicrobial Agents and Chemotherapy, 2015
- Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational StudiesDrug Safety, 2015
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionThe New England Journal of Medicine, 2014
- Staphylococcus aureus Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset InfectionsClinical Infectious Diseases, 2014
- Increased US Emergency Department Visits for Skin and Soft Tissue Infections, and Changes in Antibiotic Choices, During the Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureusAnnals of Emergency Medicine, 2008
- Skin and Soft-Tissue Infections Caused by Methicillin-ResistantStaphylococcus aureusThe New England Journal of Medicine, 2007
- Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure InfectionsClinical Infectious Diseases, 2005
- Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptideJournal of Antimicrobial Chemotherapy, 2005
- Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue InfectionsClinical Infectious Diseases, 2003